Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Beth Hecht sold 16,666 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total transaction of $133,827.98. Following the transaction, the insider owned 1,161,128 shares of the company’s stock, valued at approximately $9,323,857.84. The trade was a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Beth Hecht also recently made the following trade(s):
- On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.06, for a total value of $101,002.02.
- On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.23, for a total value of $103,835.41.
Xeris Biopharma Stock Performance
NASDAQ XERS opened at $8.28 on Friday. The stock has a market capitalization of $1.43 billion, a P/E ratio of 138.00 and a beta of 0.62. The business has a 50 day simple moving average of $6.61 and a 200 day simple moving average of $6.63. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. Xeris Biopharma Holdings, Inc. has a one year low of $4.62 and a one year high of $10.08.
Hedge Funds Weigh In On Xeris Biopharma
A number of institutional investors have recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares in the last quarter. Millennium Management LLC increased its stake in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP acquired a new position in Xeris Biopharma during the first quarter worth $170,000. 42.75% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on XERS. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.80.
Check Out Our Latest Stock Report on XERS
Xeris Biopharma Company Profile
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Stories
- Five stocks we like better than Xeris Biopharma
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
